Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drugs, Investigational | 3 | 2024 | 36 | 1.170 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 139 | 0.990 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2024 | 22 | 0.980 |
Why?
|
| Data Collection | 1 | 2023 | 370 | 0.700 |
Why?
|
| Research Design | 1 | 2021 | 620 | 0.530 |
Why?
|
| Immunoglobulin A | 6 | 2006 | 89 | 0.470 |
Why?
|
| Immunoglobulin J-Chains | 5 | 2002 | 10 | 0.440 |
Why?
|
| United States | 5 | 2024 | 7581 | 0.320 |
Why?
|
| Biological Products | 2 | 2024 | 178 | 0.310 |
Why?
|
| Colitis, Ulcerative | 2 | 2003 | 800 | 0.230 |
Why?
|
| Cecum | 3 | 2001 | 78 | 0.220 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2021 | 42 | 0.210 |
Why?
|
| Gastritis | 1 | 2003 | 38 | 0.190 |
Why?
|
| Pseudolymphoma | 1 | 2002 | 7 | 0.180 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2002 | 7 | 0.180 |
Why?
|
| Ileal Diseases | 1 | 2002 | 24 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 753 | 0.180 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2002 | 39 | 0.180 |
Why?
|
| Intestinal Mucosa | 7 | 2006 | 825 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 202 | 0.180 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2021 | 29 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2020 | 25 | 0.160 |
Why?
|
| Dysgammaglobulinemia | 1 | 2000 | 4 | 0.160 |
Why?
|
| Herpes Genitalis | 1 | 2000 | 8 | 0.160 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 20 | 0.160 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 65 | 0.160 |
Why?
|
| Vaginal Diseases | 1 | 2000 | 27 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 59 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 36 | 0.150 |
Why?
|
| Escherichia coli | 2 | 2001 | 562 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2021 | 403 | 0.150 |
Why?
|
| Risk Management | 1 | 2019 | 38 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 289 | 0.150 |
Why?
|
| Fimbriae Proteins | 1 | 1999 | 15 | 0.150 |
Why?
|
| Fimbriae, Bacterial | 1 | 1999 | 24 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 183 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 168 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 7 | 2017 | 1099 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2017 | 42 | 0.130 |
Why?
|
| Secretory Component | 1 | 1996 | 1 | 0.120 |
Why?
|
| Humans | 15 | 2024 | 93132 | 0.120 |
Why?
|
| Bacterial Adhesion | 3 | 2001 | 83 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1910 | 0.110 |
Why?
|
| Mice | 13 | 2017 | 12230 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2002 | 808 | 0.110 |
Why?
|
| Rotavirus | 2 | 2006 | 10 | 0.110 |
Why?
|
| Rotavirus Infections | 2 | 2006 | 10 | 0.110 |
Why?
|
| Mice, Mutant Strains | 4 | 2006 | 217 | 0.100 |
Why?
|
| Heat-Shock Proteins | 2 | 2003 | 177 | 0.090 |
Why?
|
| Aluminum Compounds | 1 | 2011 | 6 | 0.090 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 9 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1727 | 0.090 |
Why?
|
| Colon | 3 | 2003 | 540 | 0.090 |
Why?
|
| Chlorides | 1 | 2011 | 100 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1385 | 0.080 |
Why?
|
| Liver | 1 | 1995 | 1206 | 0.080 |
Why?
|
| Hepatectomy | 3 | 2001 | 177 | 0.080 |
Why?
|
| Vaccines | 1 | 2011 | 84 | 0.080 |
Why?
|
| Animals | 13 | 2017 | 27973 | 0.080 |
Why?
|
| Enterotoxins | 3 | 2006 | 22 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2023 | 2434 | 0.070 |
Why?
|
| Asthma | 1 | 2017 | 1039 | 0.070 |
Why?
|
| Capsid Proteins | 2 | 2006 | 26 | 0.070 |
Why?
|
| Bacterial Toxins | 3 | 2006 | 112 | 0.070 |
Why?
|
| Antigens, Viral | 2 | 2006 | 122 | 0.070 |
Why?
|
| Giardia | 1 | 2006 | 1 | 0.060 |
Why?
|
| Giardiasis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2006 | 5 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2006 | 244 | 0.060 |
Why?
|
| Immunity, Mucosal | 2 | 2006 | 71 | 0.060 |
Why?
|
| Virus Shedding | 1 | 2006 | 19 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1908 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 2024 | 16 | 0.050 |
Why?
|
| Aged | 1 | 2021 | 20395 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2003 | 22 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2003 | 71 | 0.050 |
Why?
|
| Capsid | 1 | 2002 | 20 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 481 | 0.050 |
Why?
|
| Rectum | 1 | 2003 | 148 | 0.050 |
Why?
|
| Base Sequence | 2 | 1996 | 2207 | 0.050 |
Why?
|
| Mice, Knockout | 4 | 2006 | 2121 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 2889 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2021 | 15 | 0.040 |
Why?
|
| Child | 2 | 2003 | 7273 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 368 | 0.040 |
Why?
|
| Infant | 2 | 2011 | 3156 | 0.040 |
Why?
|
| Internationality | 1 | 2021 | 78 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2006 | 320 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 226 | 0.040 |
Why?
|
| Adalimumab | 1 | 2020 | 92 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2006 | 465 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 537 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2006 | 2827 | 0.040 |
Why?
|
| Starvation | 1 | 1999 | 22 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1519 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 367 | 0.040 |
Why?
|
| Adhesins, Escherichia coli | 1 | 1999 | 3 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2003 | 700 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 2479 | 0.040 |
Why?
|
| Cell Line | 2 | 2002 | 2458 | 0.040 |
Why?
|
| Public Health | 1 | 2019 | 152 | 0.030 |
Why?
|
| Vaccination | 1 | 2000 | 303 | 0.030 |
Why?
|
| Epithelium | 1 | 1999 | 314 | 0.030 |
Why?
|
| Female | 7 | 2021 | 48542 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1997 | 23 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 873 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 1997 | 56 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2000 | 463 | 0.030 |
Why?
|
| Adult | 3 | 2021 | 27849 | 0.030 |
Why?
|
| Milk | 1 | 1996 | 56 | 0.030 |
Why?
|
| Lactation | 1 | 1996 | 55 | 0.030 |
Why?
|
| Influenza A virus | 1 | 1997 | 172 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 133 | 0.030 |
Why?
|
| Mammary Glands, Animal | 1 | 1996 | 81 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 119 | 0.030 |
Why?
|
| Bile | 1 | 1995 | 60 | 0.030 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 61 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 1996 | 193 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 161 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 449 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1997 | 288 | 0.030 |
Why?
|
| Biological Transport | 1 | 1995 | 398 | 0.030 |
Why?
|
| Male | 5 | 2021 | 44355 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 528 | 0.030 |
Why?
|
| Dogs | 1 | 1995 | 632 | 0.030 |
Why?
|
| Genotype | 1 | 1999 | 1866 | 0.030 |
Why?
|
| Administration, Intranasal | 2 | 2006 | 140 | 0.030 |
Why?
|
| HSP72 Heat-Shock Proteins | 2 | 2003 | 24 | 0.020 |
Why?
|
| Permeability | 2 | 2002 | 143 | 0.020 |
Why?
|
| Patch Tests | 1 | 2011 | 4 | 0.020 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2011 | 3 | 0.020 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 17 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 32 | 0.020 |
Why?
|
| Immunoglobulin A, Secretory | 2 | 2002 | 18 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 9070 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2006 | 22 | 0.020 |
Why?
|
| Cholera Toxin | 1 | 2006 | 21 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 68 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 2006 | 55 | 0.010 |
Why?
|
| Immunization | 1 | 2006 | 154 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2427 | 0.010 |
Why?
|
| Immunity | 1 | 2006 | 153 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2006 | 166 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 174 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 6922 | 0.010 |
Why?
|
| Feces | 1 | 2006 | 360 | 0.010 |
Why?
|
| Escherichia coli Proteins | 1 | 2006 | 179 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 9550 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 710 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 459 | 0.010 |
Why?
|
| Intestines | 1 | 2006 | 433 | 0.010 |
Why?
|
| Metronidazole | 1 | 2003 | 26 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2003 | 3431 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 135 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2002 | 47 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 101 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 2003 | 94 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 151 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 2002 | 98 | 0.010 |
Why?
|
| Glycosylation | 1 | 2002 | 134 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 124 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2002 | 87 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2002 | 37 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 392 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 312 | 0.010 |
Why?
|
| Tight Junctions | 1 | 2002 | 154 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 672 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2001 | 69 | 0.010 |
Why?
|
| Mannitol | 1 | 2001 | 49 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2003 | 453 | 0.010 |
Why?
|
| Electric Impedance | 1 | 2001 | 115 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 429 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 683 | 0.010 |
Why?
|
| Actins | 1 | 2002 | 467 | 0.010 |
Why?
|
| Ion Transport | 1 | 1999 | 82 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 556 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 1304 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1786 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 612 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 389 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 703 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 27535 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 833 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1997 | 21 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 2020 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1997 | 68 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1997 | 102 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1719 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1997 | 215 | 0.010 |
Why?
|
| Virus Replication | 1 | 1997 | 284 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 2545 | 0.010 |
Why?
|
| Lung | 1 | 1997 | 1359 | 0.000 |
Why?
|